Plasma brain natriuretic peptide as a parameter to assess efficacy of continuous intravenous infusion of prostacyclin (epoprostenol) to treat severe primary pulmonary hypertension: a case report.
Continuous intravenous infusion of prostacyclin (epoprostenol) as a treatment for primary pulmonary hypertension (PPH) definitely improves the patient's quality of life, but few accurate parameters have been found to evaluate the efficacy of the treatment. We observed a patient with severe PPH whose plasma brain natriuretic peptide (BNP) level changed significantly as her condition and symptoms changed. Plasma BNP may be considered as one of the parameters for assessing the efficacy of prostacyclin treatment.
Wakaumi
M
M
Department of Cardiology, The Heart Institute of Japan, Tokyo Women's Medical University, Japan.
Shiga
T
T
Nozaki
K
K
Fujiu
K
K
Shimaya
K
K
Ishizuka
N
N
Matsuda
N
N
Kasanuki
H
H
D000293:Adolescent; D000959:Antihypertensive Agents / Q000008:administration & dosage*; D015415:Biomarkers / Q000032:analysis; D004305:Dose-Response Relationship, Drug; D004334:Drug Administration Schedule; D011464:Epoprostenol / Q000008:administration & dosage*; D005260:Female; D006801:Humans; D006976:Hypertension, Pulmonary / Q000175:diagnosis* / Q000188:drug therapy*; D007262:Infusions, Intravenous; D020097:Natriuretic Peptide, Brain / Q000097:blood*; D011379:Prognosis; D012680:Sensitivity and Specificity; D012720:Severity of Illness Index; D016896:Treatment Outcome
D000959:Antihypertensive Agents; D015415:Biomarkers; D020097:Natriuretic Peptide, Brain; D011464:Epoprostenol